ADL 100101

Drug Profile

ADL 100101

Alternative Names: ADL 0101; ADL 10-0101

Latest Information Update: 22 Aug 2006

Price : $50

At a glance

  • Originator Adolor Corporation
  • Class
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Pruritus; Visceral pain

Most Recent Events

  • 10 Jul 2006 Discontinued - Phase-I for Pruritus in USA (Topical)
  • 10 Jul 2006 Discontinued - Phase-II for Visceral pain in USA (IV-injection)
  • 10 Jul 2006 Discontinued - Preclinical for Pruritus in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top